Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07735494

Physical Activity Promotion and Clinical Remission in Severe Asthma

Physical Activity Promotion and Clinical Remission in Severe Asthma — Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT07735494.

📅 30 Jul 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07735494
Sponsor
University of Leeds
Start
2026-07
ClinicaliQ Trial Snapshot
  • Physical Activity Promotion and Clinical Remission in Severe Asthma — Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT07735494.
  • What is being tested: A structured physical activity promotion programme combined with tezepelumab (a biologic therapy) versus standard care alone, to determine if exercise intervention enhances clinical remission rates in adults with severe asthma.
  • Patient eligibility overview: Adults with severe asthma who are candidates for tezepelumab treatment; this targets patients with difficult-to-control disease despite optimised conventional therapy and other biologic options.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This study will investigate whether a structured physical activity promotion programme, delivered alongside standard treatment with tezepelumab, increases the proportion of adults with severe asthma achieving clinical remission compared with standard care alone. Although biologic therapies have improved asthma control for many people with severe asthma, many individuals remain physically inactive, experience reduced exercise tolerance, and continue to report symptoms that affect their quality of life. Physical inactivity may represent a modifiable factor that limits the achievement of optimal health outcomes. Adults with severe asthma who are starting tezepelumab as…

Eligibility Snapshot
  • : * Adults aged 18-70 years. * Physician-diagnosed severe asthma. * Eligible for tezepelumab according to NICE TA880. * History of ≥3 asthma exacerbations requiring oral corticosteroids in the previous 12 months or receiving maintenance oral corticosteroid therapy. * Objective confirmation of asthma, including bronchodilator reversibility, bronchial hyperresponsiveness and/or variable airflow obstruction, as part of routine clinical assessment. * Decision to commence tezepelumab made by the treating multidisciplinary severe asthma team prior to study enrolment. * Able and willing to provide written informed consent.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
UK Achondroplasia Network’s consensus guideline for multidisciplinary care of children and young people with achondroplasia: NICE review
Respiratory / COPD / Asthma · 19 May 2026
Establish multidisciplinary team review at diagnosis and at key developmental stages (infancy, pre-school, school age, adolescence) to monitor for complications including spinal…
View guideline →
Guideline
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
Respiratory / COPD / Asthma · 17 Jun 2026
Mepolizumab is recommended for patients with uncontrolled COPD and blood eosinophils ≥100 cells/μL; check eosinophil levels before initiating treatment as this is…
View guideline →
Clinical Brief
There’s a reason child vaccination rates are falling – and it’s not social media
Respiratory / COPD / Asthma · BBC Health · 03 Aug 2026
Vaccination rates declining across UK: Child immunisation coverage is falling below safe thresholds needed for herd immunity, creating vulnerability to vaccine-preventable disease…
View brief →
Clinical Brief
Children keep dying in a country that made huge progress on measles
Respiratory / COPD / Asthma · BBC Health · 08 Jul 2026
Measles Outbreak in Bangladesh: Key Clinical Points Bangladesh is experiencing a major measles outbreak with >120,000 suspected and confirmed cases, indicating potential…
View brief →
Clinical Brief
Over one million children referred for mental healthcare – with anxiety the main reason
Respiratory / COPD / Asthma · BBC Health · 29 Jun 2026
Over one million children in England have been referred for mental healthcare, with anxiety as the leading presenting complaint, indicating a substantial…
View brief →
Clinical Brief
Surviving in the wild for suicide awareness
Respiratory / COPD / Asthma · BBC Health · 11 Jul 2026
Suicide prevention awareness campaigns continue to gain public visibility through high-profile individual initiatives, which may help reduce stigma in clinical settings Healthcare…
View brief →